Creative Commons source reading · ALS and frontotemporal degeneration
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.
M Catarina Silva; Fleur M Ferguson; Quan Cai; Katherine A Donovan; Ghata Nandi; Debasis Patnaik; Tinghu Zhang; Hai-Tsang Huang; Diane E Lucente; Bradford C Dickerson; Timothy J Mitchison; Eric S Fischer; Nathanael S Gray; Stephen J Haggarty
Originally published in eLife · 2019-03-25
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas. Positron emission tomography (PET) tracers that bind to pathological tau are used in diagnosis, but there are no current therapies to eliminate these tau species. We employed targeted protein degradation technology to convert a tau PET-probe into a functional degrader of pathogenic tau. The hetero-bifunctional molecule QC-01-175 was designed to engage both tau and Cereblon (CRBN), a substrate-receptor for the E3-ubiquitin ligase CRL4 CRBN , to trigger tau ubiquitination and proteasomal degradation. QC-01-175 effected clearance of tau in frontotemporal dementia (FTD) patient-derived neuronal cell models, with minimal effect on tau from neurons of healthy controls, indicating specificity for disease-relevant forms. QC-01-175 also rescued stress vulnerability in FTD neurons, phenocopying CRISPR-mediated MAPT -knockout. This work demonstrates that aberrant tau in FTD patient-derived neurons is amenable to targeted degradation, representing an important advance for therapeutics.
Discussion
In this study, we established that disease-relevant forms of tau and P-tau in FTD patient-derived neuronal cell models are amenable to targeted degradation and characterize the tool compound QC-01–175 as an effective tau degrader. We developed a BLI in vitro assay to assess QC-01–175 binding to recombinant tau species relative to T807. Despite detecting binding, QC-01–175 and T807 showed micromolar affinities to immobilized, soluble protein, independent of the presence of a tau variant. E.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
